The strong revenue growth, substantial cash position, and positive clinical trial progress for VYD2311 create a favorable outlook. Traders should monitor the mid-2026 top-line data readout from the DECLARATION trial as a key catalyst, which could significantly impact the stock if results are positive.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $1.74entry
- T+1 · 9mo ago +3.45%α +4.76% · $1.80
- T+5 · 8mo ago +3.45%α +5.69% · $1.80
- T+20 · 8mo ago −26.44%α −22.65% · $1.28
- T+60 · 6mo ago −29.89%α −41.19% · $1.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd reported strong financial and clinical progress, with Q4 2025 PEMGARDA net product revenue of $17.2 million (25% YoY growth) and a year-end cash position of $226.7 million after raising over $200 million in 2H 2025. The company's pivotal DECLARATION Phase 3 trial for its COVID-19 antibody VYD2311 is fully enrolled with top-line data expected mid-2026, and the FDA granted Fast Track designation for the candidate.
Key Financial Metrics
Key Facts
- Achieved Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
- 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
- Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026
- Fast Track designation for VYD2311 granted by FDA in December 2025
- DECLARATION trial on track with full enrollment achieved
- Distinguished scientist and physician Michael Mina, M.D., Ph.D., appointed Chief Medical Officer
Financial Impact
Q4 2025 revenue of $17.2 million (25% YoY growth) and full-year 2025 revenue of $53.4 million (111% YoY growth)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| PEMGARDA | $53.4M | +110.5% |
Risk Factors
- Clinical trial results may not meet expectations
- Regulatory approval is not guaranteed even with Fast Track designation
- Future revenue depends on successful commercialization of pipeline products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092528 |
| Document: d118119d8k.htm | 0001193125-26-092528 |
| Document: d118119dex992.htm | 0001193125-26-092528 |
| Document: 0001193125-26-092528-index-headers.html | 0001193125-26-092528 |
| Document: 0001193125-26-092528-index.html | 0001193125-26-092528 |
| Document: 0001193125-26-092528.txt | 0001193125-26-092528 |
Track record
19 reports on IVVD
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers